All In Biotech

NDA 018651 · Alkem Labs LTD

Marinol

Dronabinol · Oral · Cannabinoid

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Mar 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1985

May 31, 1985

Approved uses

2

Original approval plus efficacy supplements

Registered trials

354

68 Phase 3, 52 recruiting

FAERS reports

8,051

6,027 serious, 1,678 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 13, 2026.

Dronabinol capsules are indicated in adults for the treatment of: • anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). • nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Dronabinol capsules is a cannabinoid indicated in adults for the treatment of: • Anorexia associated with weight loss in patients with AIDS. ( 1 ) • Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. ( 1 )

Mechanism: Dronabinol is an orally active cannabinoid which has complex effects on the CNS, including central sympathomimetic activity. Cannabinoid receptors have been discovered in neural tissues. These receptors may play a role in mediating the effects of dronabinol.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 22, 1992 Supplement 6 · Efficacy
  • May 31, 1985 Original approval · Type 1 - New Molecular Entity · priority review Review
3 products under this application
  • MARINOL · DRONABINOL 10MG · CAPSULE, ORAL · Prescription · TE AB
  • MARINOL · DRONABINOL 2.5MG · CAPSULE, ORAL · Prescription · TE AB
  • MARINOL · DRONABINOL 5MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dronabinol" as an intervention, any sponsor and status, largest first.

All 354 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea901
  • fatigue716
  • diarrhoea619
  • death599
  • vomiting589
  • off label use523
  • decreased appetite455
  • pain442
  • weight decreased421
  • dyspnoea387
  • asthenia383
  • toxicity to various agents353

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200489
200584
2006121
2007108
200876
2009102
2010129
2011150
2012181
2013233
2014293
2015429
2016518
2017557
2018664
2019724
2020662
2021542
2022517
2023574
2024562
2025462
2026274

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 153 on PubMed

Sponsor: Alkem Labs LTD

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.